First-In-Human Study of KHN922 for Injection
ConditionAdvanced Solid Tumors Cancer
Trial statusNot yet recruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorChengdu Kanghong Biotech Co., Ltd.
About this trial
A Phase 1/2 Study of KHN922 for Injection to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity in Patients with Advanced Solid Tumors
Eligibility criteria
Qualifiers
None
Disqualifiers
Major surgery within 4 weeks or will be expected to require major surgical treatment during the study period.
Radical radiotherapy or chest palliative radiotherapy within 4 weeks, or palliative radiotherapy at any other sites except chest within 2 weeks.
Antibody-based anti-cancer therapies, macromolecular protein products or cytotherapies within 4 weeks.
Hormonal anti-tumor therapy within 2 weeks.
Trial design
Treatments tested in this trial
- KHN922 for injection
Treatment groups
276 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov